ENDRA Life Sciences Inc. — Director's Dealing 2017

May 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ENDRA Life Sciences Inc. (NDRA)
CIK: 0001681682
Period of Report: 2017-05-12

Reporting Person: Wells David R. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-12	Common Stock	A	18833	$0.00	Acquired	18833	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-12	Stock Options	$5.00	A	15000	Acquired	2021-05-12	Common Stock (15000)	Direct
2017-05-12	Stock Options	$5.00	A	7000	Acquired	2022-05-12	Common Stock (7000)	Direct

Footnotes

F1: Award of restricted stock granted pursuant to the Issuer's 2016 Omnibus Incentive Plan.

F2: These Stock Options become exercisable in twelve equal quarterly installments beginning on August 12, 2017.